ProCE Banner Activity

Why I Am Excited About Long-Acting ART and Why I Think It Is Here to Stay!

Conference Coverage
Clinical Thought
A long-acting injectable ART option has reached the clinic in Canada and is anticipated to soon be available in other regions of the world. How will this new option and other long-acting strategies coming down the pipeline affect clinical care of our patients with HIV, and what are the specific implications for patient and provider experience in the United Kingdom? Here’s my take.

Released: April 06, 2020

Expiration: April 05, 2021

Share

Faculty

Chloe Orkin

Chloe Orkin, MBChB, FRCP, MD

Professor of Infection and Inequities
Dean for Healthcare Transformation
Queen Mary University of London
Faculty of Medicine and Dentistry
London, United Kingdom

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Gilead

ViiV Healthcare

Faculty Disclosure

Primary Author

Chloe Orkin, MBChB, FRCP, MD

Professor of Infection and Inequities
Dean for Healthcare Transformation
Queen Mary University of London
Faculty of Medicine and Dentistry
London, United Kingdom

Chloe Orkin, MBChB, FRCP, MD, has disclosed that she has served on an advisory board/panel or speakers bureau for and has received funds for research support from Gilead Sciences, GlaxoSmithKline, Janssen, MSD, and ViiV Healthcare.